Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Evogene Ltd is a biotechnology business based in the US. Evogene shares (EVGN) are listed on the NASDAQ and all prices are listed in US Dollars. Evogene employs 131 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$3.48|
|52-week range||$1.05 - $10.24|
|50-day moving average||$3.33|
|200-day moving average||$4.78|
|Wall St. target price||$15.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.72|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-07-22)||N/A|
|1 month (2021-07-02)||6.42%|
|3 months (2021-04-30)||-20.18%|
|6 months (2021-01-29)||N/A|
|1 year (2020-07-29)||N/A|
|2 years (2019-07-29)||N/A|
|3 years (2018-07-29)||N/A|
|5 years (2016-07-29)||N/A|
|Revenue TTM||$1.3 million|
|Gross profit TTM||$466,000|
|Return on assets TTM||-19.23%|
|Return on equity TTM||-38.11%|
|Market capitalisation||$117 million|
TTM: trailing 12 months
There are currently 694,898 Evogene shares held short by investors – that's known as Evogene's "short interest". This figure is 11.6% down from 786,220 last month.
There are a few different ways that this level of interest in shorting Evogene shares can be evaluated.
Evogene's "short interest ratio" (SIR) is the quantity of Evogene shares currently shorted divided by the average quantity of Evogene shares traded daily (recently around 352740.10152284). Evogene's SIR currently stands at 1.97. In other words for every 100,000 Evogene shares traded daily on the market, roughly 1970 shares are currently held short.
However Evogene's short interest can also be evaluated against the total number of Evogene shares, or, against the total number of tradable Evogene shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Evogene's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Evogene shares in existence, roughly 20 shares are currently held short) or 0.0178% of the tradable shares (for every 100,000 tradable Evogene shares, roughly 18 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Evogene.
Find out more about how you can short Evogene stock.
We're not expecting Evogene to pay a dividend over the next 12 months.
Evogene's shares were split on a 1:2 basis on 18 November 2013. So if you had owned 2 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Evogene shares – just the quantity. However, indirectly, the new 100% higher share price could have impacted the market appetite for Evogene shares which in turn could have impacted Evogene's share price.
Over the last 12 months, Evogene's shares have ranged in value from as little as $1.05 up to $10.24. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Evogene's is 0.7177. This would suggest that Evogene's shares are less volatile than average (for this exchange).
Evogene Ltd. , together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton.
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
Everything we know about the RenovoRx IPO, plus information on how to buy in.
Everything we know about the Draganfly IPO, plus information on how to buy in.
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
Everything we know about the Marpai IPO, plus information on how to buy in.
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.